These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 34588227)

  • 21. Early impact of sequential introduction of 7-valent and 13-valent pneumococcal conjugate vaccine on IPD in Israeli children <5 years: an active prospective nationwide surveillance.
    Ben-Shimol S; Greenberg D; Givon-Lavi N; Schlesinger Y; Somekh E; Aviner S; Miron D; Dagan R
    Vaccine; 2014 Jun; 32(27):3452-9. PubMed ID: 24690148
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Invasive pneumococcal disease in England and Wales: what is the true burden and what is the potential for prevention using 7 valent pneumococcal conjugate vaccine?
    McIntosh ED; Booy R
    Arch Dis Child; 2002 Jun; 86(6):403-6. PubMed ID: 12023167
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Association of tiered restrictions and a second lockdown with COVID-19 deaths and hospital admissions in England: a modelling study.
    Davies NG; Barnard RC; Jarvis CI; Russell TW; Semple MG; Jit M; Edmunds WJ; ;
    Lancet Infect Dis; 2021 Apr; 21(4):482-492. PubMed ID: 33357518
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The herd effects of infant PCV7/PCV13 sequential implementation on adult invasive pneumococcal disease, six years post implementation; a nationwide study in Israel.
    Regev-Yochay G; Katzir M; Strahilevitz J; Rahav G; Finn T; Miron D; Maor Y; Chazan B; Schindler Y; Dagan R;
    Vaccine; 2017 Apr; 35(18):2449-2456. PubMed ID: 28342668
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Risk of Invasive Pneumococcal Disease in Children with Sickle Cell Disease in England: A National Observational Cohort Study, 2010-2015.
    Oligbu G; Collins S; Sheppard C; Fry N; Dick M; Streetly A; Ladhani S
    Arch Dis Child; 2018 Jul; 103(7):643-647. PubMed ID: 29282225
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Rapid increase in non-vaccine serotypes causing invasive pneumococcal disease in England and Wales, 2000-17: a prospective national observational cohort study.
    Ladhani SN; Collins S; Djennad A; Sheppard CL; Borrow R; Fry NK; Andrews NJ; Miller E; Ramsay ME
    Lancet Infect Dis; 2018 Apr; 18(4):441-451. PubMed ID: 29395999
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Similar impact and replacement disease after pneumococcal conjugate vaccine introduction in hospitalised children with invasive pneumococcal disease in Europe and North America.
    Palmu AA; De Wals P; Toropainen M; Ladhani SN; Deceuninck G; Knol MJ; Sanders EAM; Miller E
    Vaccine; 2021 Mar; 39(11):1551-1555. PubMed ID: 33610373
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Invasive pneumococcal disease due to 22F and 33F in England: A tail of two serotypes.
    Amin-Chowdhury Z; Groves N; Sheppard CL; Litt D; Fry NK; Andrews N; Ladhani SN
    Vaccine; 2021 Apr; 39(14):1997-2004. PubMed ID: 33715901
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evaluation of impact of 23 valent pneumococcal polysaccharide vaccine following 7 valent pneumococcal conjugate vaccine in Australian Indigenous children.
    Jayasinghe S; Chiu C; Menzies R; Lehmann D; Cook H; Giele C; Krause V; McIntyre P
    Vaccine; 2015 Nov; 33(48):6666-74. PubMed ID: 26519550
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Changes in the Nature and Severity of Invasive Pneumococcal Disease in Children Before and After the Seven-valent and Thirteen-valent Pneumococcal Conjugate Vaccine Programs in Calgary, Canada.
    Ricketson LJ; Conradi NG; Vanderkooi OG; Kellner JD
    Pediatr Infect Dis J; 2018 Jan; 37(1):22-27. PubMed ID: 28737622
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Impact of the pneumococcal conjugate vaccines on invasive pneumococcal disease in France, 2001-2012.
    Lepoutre A; Varon E; Georges S; Dorléans F; Janoir C; Gutmann L; Lévy-Bruhl D; ;
    Vaccine; 2015 Jan; 33(2):359-66. PubMed ID: 25448105
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Invasive pneumococcal disease in Canada 2010-2017: The role of current and next-generation higher-valent pneumococcal conjugate vaccines.
    Dion SB; Major M; Gabriela Grajales A; Nepal RM; Cane A; Gessner B; Vojicic J; Suaya JA
    Vaccine; 2021 May; 39(22):3007-3017. PubMed ID: 33824041
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Characteristics and Serotype Distribution of Childhood Cases of Invasive Pneumococcal Disease Following Pneumococcal Conjugate Vaccination in England and Wales, 2006-2014.
    Oligbu G; Collins S; Andrews N; Sheppard CL; Fry NK; Slack MPE; Borrow R; Ladhani SN
    Clin Infect Dis; 2017 Oct; 65(7):1191-1198. PubMed ID: 29309553
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Invasive pneumococcal disease, comorbidities, and polysaccharide vaccine use in children aged 5-15 years in England and Wales.
    Ladhani SN; Andrews NJ; Waight P; Borrow R; Slack MP; Miller E
    Clin Infect Dis; 2014 Feb; 58(4):517-25. PubMed ID: 24300040
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Impact of 13-valent pneumococcal conjugate vaccination on invasive pneumococcal disease in children under 15 years old in Madrid, Spain, 2007 to 2016: The HERACLES clinical surveillance study.
    Picazo JJ; Ruiz-Contreras J; Casado-Flores J; Negreira S; Baquero-Artigao F; Hernández-Sampelayo T; Otheo E; Amo MD; Méndez C;
    Vaccine; 2019 Apr; 37(16):2200-2207. PubMed ID: 30902478
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Impact of the 13-valent pneumococcal conjugate vaccine (pcv13) on invasive pneumococcal disease and carriage in Alaska.
    Bruce MG; Singleton R; Bulkow L; Rudolph K; Zulz T; Gounder P; Hurlburt D; Bruden D; Hennessy T
    Vaccine; 2015 Sep; 33(38):4813-9. PubMed ID: 26247901
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The changing epidemiology of invasive pneumococcal disease after PCV13 vaccination in a country with intermediate vaccination coverage.
    Ciruela P; Izquierdo C; Broner S; Muñoz-Almagro C; Hernández S; Ardanuy C; Pallarés R; Domínguez A; Jané M;
    Vaccine; 2018 Nov; 36(50):7744-7752. PubMed ID: 30473132
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The incremental burden of invasive pneumococcal disease associated with a decline in childhood vaccination using a dynamic transmission model in Japan: A secondary impact of COVID-19.
    Kitano T; Aoki H
    Comput Biol Med; 2021 Jun; 133():104429. PubMed ID: 33930765
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Invasive pneumococcal disease in England and Wales: vaccination implications.
    Sleeman K; Knox K; George R; Miller E; Waight P; Griffiths D; Efstratiou A; Broughton K; Mayon-White RT; Moxon ER; Crook DW; ;
    J Infect Dis; 2001 Jan; 183(2):239-246. PubMed ID: 11120930
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effectiveness of a 3 + 0 pneumococcal conjugate vaccine schedule against invasive pneumococcal disease among a birth cohort of 1.4 million children in Australia.
    Gidding HF; McCallum L; Fathima P; Moore HC; Snelling TL; Blyth CC; Jayasinghe S; Giele C; de Klerk N; Andrews RM; McIntyre PB;
    Vaccine; 2018 May; 36(19):2650-2656. PubMed ID: 29627233
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.